에 대한 최신 뉴스 AEON Biopharma (AMEX:AEON) 주식

AEON Biopharma

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma Inc

AEON CREDIT SERVICE ASIA by Aeon Credit Service Asia Company Ltd

AEON Co Ltd

AEON DELIGHT CO LTD by Aeon Delight Co., Ltd.

AEON DELIGHT Co Ltd

AEON FANTASY CO LTD by AEON Fantasy Co., Ltd.

AEON FINCL SVCS JPN ORD by Aeon Financial Services Co., Ltd.

AEON Financial Service Co Ltd

AEON Mall Co Ltd

AEON REIT INVT CORP by AEON REIT INVT CORP.

AEON REIT Investment Corp

Aeon Credit Service (Asia) Co Ltd

Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.81) by 23.46 percent. This is a 0.99 percent increase over losses of $(1.01) per share from the same period last year.

Earnings

Earnings Misses

News

SLDB

Solid Biosciences Q4 2024 GAAP EPS $(1.00) Misses $(0.81) Estimate

Dividends

American Tower Raises Quarterly Dividend From $1.62 To $1.70

Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.48 by 25 percent. This is a 30.43 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $71.17 million which beat the analyst consensus estimate of $55.10 million by 29.16 percent. This is a 38.00 percent increase over sales of $51.57 million the same period last year.

Earnings Beats

Velocity Financial Q4 Adj EPS $0.60 Beats $0.48 Estimate, Sales $71.17M Beat $55.10M Estimate

Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is unchanged from the same period last year. The company reported quarterly sales of $57.78 million which beat the analyst consensus estimate of $57.61 million by 0.29 percent. This is a 12.71 percent decrease over sales of $66.19 million the same period last year.

Information Servs Gr Q4 Adj $0.06 Beats $0.05 Estimate, Sales $57.78M Beat $57.61M Estimate

Guidance

BBAI

BigBear.ai Sees FY25 Revenue $160M-$180M

HPE CFO Says Q2, FY Outlook Reflects Current Tariff Policy

REVB

Revelation Biosciences Q4 EPS $(4.98)

NL Industries Q3 2024 GAAP EPS $0.34, Sales $33.600M Down From $40.300M YoY

ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.18 by 5.56 percent. This is a 85.27 percent decrease over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $702.80 million which missed the analyst consensus estimate of $703.30 million by 0.07 percent. This is a 0 percent decrease over sales of $702.83 million the same period last year.

MODV

ModivCare Q4 Adj $0.19 Beats $0.18 Estimate, Sales $702.80M Miss $703.30M Estimate

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.05) by 760 percent. This is a 207.14 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $43.80 million which missed the analyst consensus estimate of $54.48 million by 19.61 percent. This is a 7.98 percent increase over sales of $40.56 million the same period last year.

BigBear.ai Hldgs Q4 2024 GAAP EPS $(0.43) Misses $(0.05) Estimate, Sales $43.80M Miss $54.48M Estimate

Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16.67 percent. This is a 41.18 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $660.00 thousand which missed the analyst consensus estimate of $12.21 million by 94.59 percent. This is a 269.23 percent increase over sales of $(390.00 thousand) the same period last year.

CHMI

Cherry Hill Mortgage Q4 Adj EPS $0.10 Misses $0.12 Estimate, Sales $660.00K Miss $12.21M Estimate

TOVX

Theriva Biologics FY 2024 GAAP EPS $(19.03) Beats $(24.11) Estimate

APEI

American Public Education Expects 2025 Consolidated Revenue Of $650M – $660M (Est $648.457M)

Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 52.08 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $175.84 thousand which missed the analyst consensus estimate of $246.40 thousand by 28.64 percent. This is a 311.62 percent increase over sales of $42.72 thousand the same period last year.

SERV

Serve Robotics Q4 Adj EPS $(0.23) Misses $(0.18) Estimate, Sales $175.84K Miss $246.40K Estimate

<a href="https://www.globenewswire.com/Tracker?data=4-wEYY8qTpIGWlIctlJfnBFxXQNFzpgfzwaTBHqZaqRbPNNJpdrrXVq_JBxT9srrNqcHr7Aky4r7thPf37u-sPllobxn_WjSNceYTBx3zMQ=">Centessa Pharmaceuticals</a> plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session&nbsp;at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.
Details of the poster presentation are as follows: Title: Phase 1 Clinical Data with Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Participants Abstract Number: 2277 Presenter: Deborah Hartman, PhD, Global Scientific Head, Orexin Program Session Date and Time: Saturday, April 5, 2025, at 11:45 AM- 12:45 PM PT
Centessa's booth number is 627. AAN abstracts are available on the conference website. Centessa's poster will be available on the Centessa website at <a href="https://www.globenewswire.com/Tracker?data=K0Vfn9T9KiqgoRVG4dMoz3GF2YubgLSiu-TT9QQWhy_QM7jYgxa8fo3iywxABZNmKI7OLQyQLDpemEwzVxfObnQndDm0CADrehKppreC60rTBfvoWAb9vxS2-MixnT4eN6Lqiby7DwMFY3JI_qiT4SwMIgaeCV_Aw0EF3iVZcPOjEzin7DMJvi0fv2Sqhibhm0qVUhO91DRFMV15kPWjYA==">https://investors.centessa.com/events-presentations</a>&nbsp;after the poster presentation concludes.

Biotech

General

CNTA

Centessa Pharmaceuticals Announces Poster Presentation Of Phase 1 Clinical Data For ORX750, A Novel Orexin Receptor 2 Agonist, At The AAN 2025 Annual Meeting

a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) sees FY2025 sales of $600.000 million-$610.000 million vs $599.69 million analyst estimate.

a.k.a. Brands Holding Sees FY2025 Sales $600.000M-$610.000M vs $599.69M Est

a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) sees Q1 sales of $121.000 million-$124.000 million vs $120.95 million analyst estimate.

a.k.a. Brands Holding Sees Q1 Sales $121.000M-$124.000M vs $120.95M Est

American Public Education Expects Q1 Consolidated Revenue Of $161M – $163M (Est $161.95M), EPS Of $0.09 – $0.17 (Est $0.35)

Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.37 by 45.95 percent. The company reported quarterly sales of $4.10 billion which beat the analyst consensus estimate of $4.07 billion by 0.66 percent. This is a 4.61 percent decrease over sales of $4.30 billion the same period last year.

Comments

AEON Biopharma

뉴스

에 대한 최신 뉴스 AEON Biopharma (AMEX:AEON) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌